Siemens to acquire Bayer's Diagnostics Division

Expansion aims at high-growth molecular diagnostics market

Siemens has signed an agreement with Bayer to acquire the chemical and pharmaceutical company's Diagnostics Division.

Photo: Siemens to acquire Bayers Diagnostics Division

Siemens Medical Solutions (Med) reports that the acquisition will enable the firm to expand its position in the high-growth molecular diagnostics market. At the end of April, Siemens announced the planned acquisition of Diagnostic Products Corporation (DPC) in the USA, a leading company in immunodiagnostics. The purchase price for Bayer Diagnostics - which had sales of €1.4 billion and a double-digit EBITDA margin in fiscal 2005 - is roughly €4.2 billion.

‘Acquisition of Bayer Diagnostics is part of our targeted strategy to create the healthcare industry’s first integrated diagnostics company by combining the entire imaging diagnostics, laboratory diagnostics and clinical IT value chain under one roof,’ Dr Klaus Kleinfeld, Siemens President and CEO explained.

The company adds that the Bayer division acquisition will enable the Siemens Group to ‘...tap the rapidly growing market for molecular diagnostics based on gene analysis (nucleid acid testing). Bayer Diagnostics is also a world market-leader in clinical chemistry with a leading position in near-patient testing, laboratory automation and haematology (blood cell diagnostics).’

01.07.2006

Related articles

Photo

Sponsored • Corporate presentation at radiology congress

Bayer at ECR 2025: Less dose, more AI and sustainability

Contrast agents, AI and circular economy: Bayer presented new developments for radiology at the ECR Congress. Particular emphasis was placed on digital assistance systems and sustainability.

Photo

Sponsored • Digital solutions for radiology

How to accelerate healthcare innovation in AI

Tapping the thriving Radiology AI ecosystem, Bayer recently announced three collaboration agreements for its digital platform, Calantic Digital Solutions, as well as an AI accelerator program.

Photo

Sponsored • Earlier disease prediction and identification

The potential of AI in routine blood testing

It’s widely known that more than 70% of today’s medical decisions involve the results of laboratory tests, but the insights clinicians derive from these tests today may only be scratching the…

Related products

Subscribe to Newsletter